Methods for treating tissue are provided. In one embodiment, an adjunct material, when secured to tissue, can receive at least one physiological element released from the tissue during healing progression of the tissue, and can exhibit first and second stiffnesses in compression that are approximately constant during first and second time periods from contact with the tissue, with the second stiffness decreasing with time as a function of at least one of oxidation, enzyme-catalyzed hydrolysis, and change of pH resulting from interaction with the at least one physiological element. In another embodiment, the adjunct can receive a unit volume of fluid that causes first and second portions of the adjunct to expand according to first and second expansion behaviors that differ from one another to apply different pressures to the tissue.

Described herein are antipathogenic compositions comprising a nitride chosen from aluminum nitride, boron nitride, chromium nitride, cerium nitride, hafnium nitride, lanthanum nitride, phosphorous nitride, sulfur nitride, tantalum nitride, titanium nitride, vanadium nitride, yttrium nitride, zirconium nitride, silicon nitride, or combinations thereof, and methods of using said compositions to inactivate viruses, bacteria, and/or fungi.

Disclosed are kits for preparing a reactive graft material and injecting the graft material into a patient. Kits may include a first syringe containing a first powdered component and a second syringe containing a second powdered component that is reactive with the first powdered component when the first and second powdered components are dispersed in a diluent solution. The kits may further include a vial sealed by a septum and containing the diluent solution. A syringe connector may be included that has a connector at each end configured to make a fluidic connection to, respectively, the first syringe and the second syringe, and also comprises a passageway adapted to allow fluid to pass between the syringes when the syringes are both fluidically connected to the syringe connector. A vial adapter comprising a connector adapted for fluidically connecting to at least one of the first syringe and the second syringe, a passageway adapted to allow fluid to pass from the vial into a syringe fluidically connected to the connector of the vial adapter, and a spike in fluidic communication with the passageway of the vial adapter may be included. The spike is adapted for piercing the septum of the vial. Certain kits also contain one or more needles for delivery of the graft material to a site within a body of a patient.

The present invention relates to a wound dressing comprising hyaluronic acid-calcium and polylysine, and a manufacturing method therefor, the method comprising: (1) a step for adjusting each of the pH values of a hyaluronic acid-calcium salt and a polylysine aqueous solution to 8.4 or higher, and then mixing the hyaluronic acid-calcium salt and the polylysine aqueous solution to obtain a mixture liquid; and (2) obtaining a wound dressing from the mixture liquid obtained in Step (1).

A microsphere includes a cross-linked hydrophilic substrate, a lipophilic substrate, and a surfactant. The cross-linked hydrophilic substrate includes cross-linked sodium alginate and gelatin. The lipophilic substrate includes iodized oil, C16-C18 alkyl alcohol, and polycaprolactone. The surfactant includes polyoxyethylene stearate. The microsphere is dry or substantially solid. Prior to being used for embolization, the microsphere can be immersed in a drug containing mixture to allow the microsphere to absorb the mixture and expand, thereby loaded with the drug. A method for preparing the microsphere and a method for embolizing tumor in a subject by using the microsphere are also provided.

The present invention relates to a wound management composition consisting of full spectrum blend of active cannabinoids and at least one hemostatic agent including astringent-class hemostats, active-class hemostats, and active-mechanical-class hemostats. Further, the composition may also include at least chemical penetration enhancer that amplifies the absorption of cannabinoids, at least one local drug to prolong the pharmacologically active time of cannabinoids, at least one antibacterial agent, and at least one antifungal agent. Methods of delivery of the wound management composition and kits are also disclosed.

Various embodiments related to systems, methods, and articles for rapid inactivation of SARS-CoV-2 by silicon nitride and aluminum nitride are disclosed herein.

Implantable medical devices, composite bioactive polymeric biomaterials for forming such devices, and methods for manufacturing these biomaterials and devices are provided. The implantable medical devices are engineered, at least in part, from a composite material comprising a polymer component and a bioactive component incorporated therein to provide bioactivity to the polymeric component for the improved treatment of bone or other purposes. The implantable device may comprise a main body formed of a polymeric framework, and a bioactive glass additive incorporated into the rigid polymeric framework. The implantable device may also comprise a main body and a bioactive component that includes a polyarylretherketone (PAEK) polymer component and a bioactive additive component. The bioactive additive component is incorporated substantially throughout the polymer component to further enhance cellular activity to promote bone fusion and/or regeneration.

The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, comprising i) a calcium sulfate hemihydrate powder, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 50 weight percent based on the total weight of the particulate composition; ii) a monocalcium phosphate monohydrate powder; iii) a non-porous β-tricalcium phosphate powder; and iv) a porous β-tricalcium phosphate powder. Bone graft substitute cements made therefrom, a bone graft substitute kit comprising the particulate composition, methods of making and using the particulate composition, and articles made from the bone graft substitute cement are also provided.

Methods for treating tissue are provided. In one embodiment, an adjunct material, when secured to tissue, can receive at least one physiological element released from the tissue during healing progression of the tissue, and can exhibit first and second stiffnesses in compression that are approximately constant during first and second time periods from contact with the tissue, with the second stiffness decreasing with time as a function of at least one of oxidation, enzyme-catalyzed hydrolysis, and change of pH resulting from interaction with the at least one physiological element. In another embodiment, the adjunct can receive a unit volume of fluid that causes first and second portions of the adjunct to expand according to first and second expansion behaviors that differ from one another to apply different pressures to the tissue.